Loading…

Skeletal muscle mass and risk of advanced adenoma in surveillance colonoscopy

Background and Aim Sarcopenia has been suggested to be associated with chronic inflammation and insulin resistance. This study aimed to evaluate whether low muscle mass is associated with the incidence and recurrence of advanced colorectal adenoma. Methods We conducted a cohort study including 14 70...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2020-12, Vol.35 (12), p.2088-2095
Main Authors: Yoo, Kyung Mo, Yang, Hyo‐Joon, Park, Soo‐Kyung, Jung, Yoon Suk, Park, Jung Ho, Park, Dong Il, Sohn, Chong Il
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Sarcopenia has been suggested to be associated with chronic inflammation and insulin resistance. This study aimed to evaluate whether low muscle mass is associated with the incidence and recurrence of advanced colorectal adenoma. Methods We conducted a cohort study including 14 701 participants who underwent first‐time screening colonoscopy between 2003 and 2012 and follow‐up colonoscopy until 2017. Skeletal muscle mass was measured using a bioelectrical impedance analyzer and divided by body weight to calculate the skeletal muscle mass index (SMI). Results During a median 47 (interquartile range, 35–58) months of follow‐up, overall and advanced adenoma developed in 2988 (20.3%) and 207 (1.41%) participants, respectively. In multivariate analysis using models adjusted for baseline adenoma risk, lifestyle factors, markers for insulin resistance and chronic inflammation, and metabolic syndrome, decreasing SMI quartiles were associated with increased risk of occurrence of advanced adenoma and overall adenoma. The adjusted hazard ratios (95% confidence intervals) comparing SMI quartiles 3, 2, and 1 to quartile 4 were 1.57 (1.03–2.41), 1.22 (0.78–1.92), and 1.77 (1.13–2.76), respectively, for advanced adenoma (P for trend = 0.049) and 1.05 (0.95–1.17), 1.09 (0.98–1.21), and 1.26 (1.13–1.41), respectively, for overall adenoma (P for trend 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15082